Dean Baker and Adriane Fugh-Berman have published a critique of a study I performed in 2007, entitled "Why has longevity increased more in some states than in others?ʺ One of the conclusions I drew from that study was that medical innovation accounts for a substantial portion of recent...

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...

There are two types of prescription drug cost offsets. The first type of cost offset - from prescription drug use - is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset - the cost offset...